Table 4. Patient treatment.
| Treatment | No. of patients | % of patients |
|---|---|---|
| All |
241 |
|
| Multimodality treatment (MMT) | 18 | 7 |
| Chemotherapy (CT) | 180 | 75 |
| Best supportive care only (BSC) |
43 |
18 |
| First-line chemotherapy |
198 |
|
| Pemetrexed-based chemotherapy | 178 | 90% |
| Pemetrexed single agent | 31 | 16 |
| Pemetrexed+carboplatin | 119 | 60 |
| Pemetrexed+carboplatin+bevacizumaba | 18 | 9 |
| Pemetrexed+cisplatin | 10 | 5 |
|
Other |
20 |
10% |
| Second-line chemotherapy |
87 |
|
| Pemetrexed-based chemotherapyb | 25 | 29 |
| Gemcitabine-based regimenc | 19 | 22 |
| Vinorelbine | 22 | 25 |
| Experimental trial | 21 | 24 |
a
Treatment was delivered within an experimental trial (Ceresoli et al, 2013).
b
Including 22 pemetrexed re-challenge, 2 second-line pemetrexed and 1 patient re-challenged with raltitrexed.
c
Thirteen single agent, six combination therapy (two patients were treated with gemcitabine/vinorelbine).